J. Goldman & Co’s Novo Nordisk NVO Stock Holding History

J. Goldman & Co’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$14M	Buy	380,000 +139,900	+58%	+$6.63M	0.41%	69
2025 Q4	$12.2M	Buy	240,100 +200,100	+500%	+$10.2M	0.32%	89
2025 Q3	$2.22M	Sell	40,000 -144,200	-78%	-$8.44M	0.06%	271
2025 Q2	$12.7M	Buy	+184,200	New	+$12.5M	0.3%	108
2025 Q1	–	Sell	-40,000	Closed	-$3.44M	–	583
2024 Q4	$3.44M	Sell	40,000 -70,000	-64%	-$7.57M	0.09%	225
2024 Q3	$13.1M	Buy	+110,000	New	+$14.7M	0.37%	84
2023 Q4	–	Sell	-35,000	Closed	-$3.18M	–	433
2023 Q3	$3.18M	Buy	+35,000	New	+$3.08M	0.11%	162

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

J. Goldman & Co's NVO Position: Q1 2026 in Review

J. Goldman & Co reduced its Novo Nordisk (NVO) stake by 43% in Q1 2026, selling an estimated $401K and leaving 11,335 shares worth $417K. The position accounts for 0.01% of the portfolio, ranked #528.

J. Goldman & Co first reported a position in NVO in Q1 2024 and has held it in 4 quarters since. The position peaked at $2.77M in Q3 2025. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

J. Goldman & Co held 11,335 shares of Novo Nordisk worth $417K as of Q1 2026.
J. Goldman & Co sold 8,464 Novo Nordisk shares in Q1 2026, an estimated $401K.
Novo Nordisk made up 0.01% of J. Goldman & Co's portfolio in Q1 2026, its #528 holding.
J. Goldman & Co first reported a position in Novo Nordisk in Q1 2024 and has held it in 4 quarters since.
J. Goldman & Co's Novo Nordisk position peaked at $2.77M in Q3 2025.
1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.